Adynxx initiates AYX1 Phase 2 study to avoid post-surgical pain Adynxx.

Adynxx initiates AYX1 Phase 2 study to avoid post-surgical pain Adynxx, a clinical-stage pharmaceutical business developing a first-in-class system of therapeutics to address pain in its molecular roots, announced today that the first individual was dosed in a Stage 2 study of its business lead investigational drug applicant for the prevention of post-surgical pain, AYX1. The 90-individual, placebo-controlled study will evaluate the protection and efficacy of a single administration of AYX1 provided ahead of unilateral total knee arthroplasty to reduce acute pain and to prevent the transition to persistent pain.The confidence intervals around our estimates, although significant, are wide. One much less case of intussusception associated with the monovalent vaccine or yet another case linked to the pentavalent vaccine could possess made this comparison nonsignificant, but the relative risk would have remained elevated and still approached statistical significance. Continuing surveillance in VSD confirmation or data in other U.S. Populations could be useful in confirming the level of improved risk after rotavirus vaccination. Although we observed an elevated risk of intussusception connected with monovalent rotavirus vaccination in the VSD population, the well-documented benefits of rotavirus vaccination need to be considered.24-27 Since the start of U.S.